Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 7/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27075673 | 0.89 | KDM4C (0.43) | KDM4CJAK2KDM1ALATS1 | |
| SCHEMBL27075658 | 0.88 | LATS1 (0.51) | KDM4CJAK2LATS1 | |
| SCHEMBL27075664 | 0.86 | ZAP70 (0.44) | JAK2LATS1 | |
| SCHEMBL27075665 | 0.86 | JAK2 (0.42) | KDM4CJAK2LATS1 | |
| SCHEMBL27075661 | 0.86 | TNNI3K (0.46) | KDM4CABCG2JAK2LATS1 | |
| SCHEMBL27075657 | 0.86 | CSNK2A1 (0.47) | JAK2 | |
| SCHEMBL27075662 | 0.85 | CSNK2A1 (0.49) | KDM4CABCG2JAK2 | |
| SCHEMBL27074418 | 0.83 | ABCG2 (0.43) | KDM4CABCG2JAK2KDM1AEGFR | |
| SCHEMBL27075669 | 0.82 | JAK2 (0.40) | KDM4CJAK2LATS1 | |
| SCHEMBL27075659 | 0.81 | LATS1 (0.47) | KDM4CJAK2LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891397-B1 | Pyrido[4′,3′:4,5]pyrrolo[3,2-c][1,7]naphthyridin-10-one compounds as CK2 inhibitors | King Faisal University (SA) | 2024-02-06 | — | — | US | claimed |
| US-11891397-B1 | Pyrido[4′,3′:4,5]pyrrolo[3,2-c][1,7]naphthyridin-10-one compounds as CK2 inhibitors | King Faisal University (SA) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891397-B1 | Pyrido[4′,3′:4,5]pyrrolo[3,2-c][1,7]naphthyridin-10-one compounds as CK2 inhibitors | CKS2, PNKP, CDK2 | KDM4C 1509/4885ABCG2 3020/4885JAK2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.